p.85 抽出テキスト

arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022; 43:3997–4126. https://doi.org/10.1093/eurheartj/ehac262 120. Yndigegn T, Lindahl B, Mars K, Alfredsson J, Benatar J, Brandin L, et al. Beta-blockers after myocardial infarction and preserved ejection fraction. N Engl J Med 2024;390:1372–81. https://doi.org/10.1056/ NEJMoa2401479 121. Kristensen AMD, Rossello X, Atar D, Yndigegn T, Kimura T, Latini R, et al. Beta-blockers after myocardial infarction with normal ejection fraction. N Engl J Med 2025;394:540–50. https://doi.org/10.1056/NEJMoa 2512686 122. Damman K, ter Maaten JM, Mayne KJ, Bolignano D, Brown EM, da Costa BR, et al. 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA). Eur Heart J 2026. https://doi.org/10.1093/eurheartj/ehag098 123. Andersson C, Schou M, Schwartz B, Vasan RS, Christiansen MN, D’Souza M, et al. Incidence rates of dilated cardiomyopathy in adult first-degree relatives versus matched controls. Int J Cardiol Heart Vasc 2022;41:101065.https:// doi.org/10.1016/j.ijcha.2022.101065 124. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023;44:3503–626. https://doi.org/10.1093/eurheartj/ehad194 125. Hesse K, Bourke S, Steer J. Heart failure in patients with COPD exacerbations: looking below the tip of the iceberg. Respir Med 2022;196:106800. https://doi.org/10.1016/j.rmed.2022.106800 126. Mahmood A, Ray M, Dobalian A, Ward KD, Ahn S. Insomnia symptoms and incident heart failure: a population-based cohort study. Eur Heart J 2021; 42:4169–76. https://doi.org/10.1093/eurheartj/ehab500 127. Cowie MR, Linz D, Redline S, Somers VK, Simonds AK. Sleep disordered breathing and cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol 2021;78:608–24. https://doi.org/10.1016/j.jacc.2021.05.048 128. Vargas-Uricoechea H, Bonelo-Perdomo A. Thyroid dysfunction and heart failure: mechanisms and associations. Curr Heart Fail Rep 2017;14:48–58. https://doi.org/10.1007/s11897-017-0312-5 129. Burchill LJ, Gao L, Kovacs AH, Opotowsky AR, Maxwell BG, Minnier J, et al. Hospitalization trends and health resource use for adult congenital heart disease-related heart failure. J Am Heart Assoc 2018;7:e008775. https:// doi.org/10.1161/JAHA.118.008775 130. Dellborg M, Giang KW, Eriksson P, Liden H, Fedchenko M, Ahnfelt A, et al. Adults with congenital heart disease: trends in event-free survival past middle age. Circulation 2023;147:930–8. https://doi.org/10.1161/ CIRCULATIONAHA.122.060834 131. Bergh N, Skoglund K, Fedchenko M, Bollano E, Eriksson P, Dellborg M, et al. Risk of heart failure in congenital heart disease: a nationwide register-based cohort study. Circulation 2023;147:982–4. https://doi.org/10.1161/ CIRCULATIONAHA.122.061546 132. Papazoglou AS, Kyriakoulis KG, Barmpagiannos K, Moysidis DV, Kartas A, Chatzi M, et al. Atherosclerotic risk factor prevalence in adults with congenital heart disease: a meta-analysis. JACC Adv 2024;3:101359.https://doi.org/ 10.1016/j.jacadv.2024.101359 133. Brida M, De Rosa S, Legendre A, Ladouceur M, Dos Subira L, Scognamiglio G, et al. Acquired cardiovascular disease in adults with congenital heart disease. Eur Heart J 2023;44:4533–48. https://doi.org/10.1093/eurheartj/ehad570 134. Landstrom AP, Spears T, D’Ottavio A, Chiswell K, Sommerhalter K, Soim A, et al. Cardiovascular disease risk factors in congenital heart disease survivors are associated with heart failure. Pediatr Res 2025;97:700–6. https://doi.org/ 10.1038/s41390-024-03352-8 135. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003;361:1843–8. https://doi.org/ 10.1016/S0140-6736(03)13501-5 136. Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327: 685–91. https://doi.org/10.1056/NEJM199209033271003 137. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333:1670–6. https://doi.org/10.1056/NEJM199512213332503 138. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669–77. https://doi.org/10.1056/NEJM199209033271001 139. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385–90. https://doi.org/10.1016/s0140- 6736(00)04560-8 140. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999;33: 916–23. https://doi.org/10.1016/s0735-1097(98)00675-5 141. Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. SAVE Investigators. J Am Coll Cardiol 1997;29:229–36. https://doi.org/10. 1016/s0735-1097(96)00489-5 142. Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007;116:49–56. https://doi.org/10. 1161/CIRCULATIONAHA.106.666016 143. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–21. https://doi.org/10.1056/NEJMoa030207 144. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349: 1893–906. https://doi.org/10.1056/NEJMoa032292 145. Docherty KF, Lam CSP, Rakisheva A, Coats AJS, Greenhalgh T, Metra M, et al. Heart failure diagnosis in the general community—who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2023;25:1185–98. https://doi.org/10.1002/ejhf.2946 146. Booth RA, Hill SA, Don-Wauchope A, Santaguida PL, Oremus M, McKelvie R, et al. Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review. Heart Fail Rev 2014;19:439–51. https://doi.org/10.1007/s10741-014-9445-8 147. Clerico A, Fontana M, Zyw L, Passino C, Emdin M. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 2007;53:813–22. https://doi.org/10.1373/ clinchem.2006.075713 148. Roalfe AK, Taylor CJ, Kelder JC, Hoes AW, Hobbs FDR. Diagnosing heart failure in primary care: individual patient data meta-analysis of two European prospective studies. ESC Heart Fail 2021;8:2193–201. https://doi.org/10. 1002/ehf2.13311 149. Ordonez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: analytic considerations. Am J Cardiol 2008; 101:9–15. https://doi.org/10.1016/j.amjcard.2007.11.013 150. Myhre PL, Vaduganathan M, Claggett B, Packer M, Desai AS, Rouleau JL, et al. B-type natriuretic peptide during treatment with sacubitril/valsartan: the PARADIGM-HF trial. J Am Coll Cardiol 2019;73:1264–72. https://doi. org/10.1016/j.jacc.2019.01.018 151. Taylor CJ, Taylor KS, Jones NR, Ordonez-Mena JM, Bayes-Genis A, Hobbs FDR. Age-adjusted natriuretic peptide thresholds for a diagnosis of heart failure in the community: diagnostic accuracy study. ESC Heart Fail 2025;12: 3552–68. https://doi.org/10.1002/ehf2.15383 152. Welsh P, Campbell RT, Mooney L, Kimenai DM, Hayward C, Campbell A, et al. Reference ranges for NT-proBNP (N-terminal Pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circ Heart Fail 2022;15:e009427. https://doi.org/10. 1161/CIRCHEARTFAILURE.121.009427 153. Shetty NS, Patel N, Gaonkar M, Li P, Arora G, Arora P. Natriuretic peptide normative levels and deficiency: the National Health and Nutrition Examination Survey. JACC Heart Fail 2024;12:50–63. https://doi.org/10. 1016/j.jchf.2023.07.018 154. Hildebrandt P, Collinson PO, Doughty RN, Fuat A, Gaze DC, Gustafsson F, et al. Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. Eur Heart J 2010;31:1881–9. https://doi.org/10.1093/ eurheartj/ehq163 155. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715–31. https://doi.org/10.1002/ejhf.1494 156. Lee KH, Kim JY, Koh SB, Lee SH, Yoon J, Han SW, et al. N-terminal pro-B-type natriuretic peptide levels in the Korean general population. Korean Circ J 2010;40:645–50. https://doi.org/10.4070/kcj.2010.40.12.645 Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026